Randomized double-blind placebo-controlled trial on the potential modes of action of SheaFlex70™ in osteoarthritis

Phytotherapy Research

Volumn 24, Issue 8, 2010, Pages 1126-1131

  Cheras, Phillip A ^a   Myers, Stephen P ^a   Paul Brent, Peta Anne ^b   Outerbridge, Kerry H ^c   Nielsen, Gary V L ^d  

^a SOUTHERN CROSS UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GREENSLOPES PRIVATE HOSPITAL   (Australia)

^d MATER HOSPITAL   (Australia)

Author keywords

Biomarkers; Nutraceutical; Osteoarthritis; Randomized controlled trial

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 2; OSTEOCALCIN; PLANT EXTRACT; SHEAFLEX70; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITELLARIA PARADOXA EXTRACT;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE REMODELING; CARTILAGE DEGENERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HIP OSTEOARTHRITIS; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; MALE; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; TREE; VITELLARIA PARADOXA; CARTILAGE; CHEMISTRY; DRUG EFFECTS; HIP; KNEE; METABOLISM; MIDDLE AGED; OSTEOARTHRITIS; PATHOLOGY; PATHOPHYSIOLOGY; SAPOTACEAE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE REMODELING; CARTILAGE; DOUBLE-BLIND METHOD; FEMALE; HIP; HUMANS; KNEE; MALE; MIDDLE AGED; OSTEOARTHRITIS; PLANT EXTRACTS; SAPOTACEAE; TUMOR NECROSIS FACTOR-ALPHA;

VITELLARIA PARADOXA;

EID: 77955630853     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3075     Document Type: Article

References (25)

1. Akihisa T, Yasukawa K, Oinuma H, Kasahara Y, Yamanouchi S, Takido M, Kumaki K, Tamura T. 1996. Triterpene alcohols from the flowers of compositae and their anti-inflammatory effects. Phytochemistry 43(6): 1255-1260. (Pubitemid 27108304)
2. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, Howell D, Kaplan D, Koopman W, Longley III S, Mankin H, McShane DJ, Medsger Jr. T, Meenan R, Mikkelsen W, Moskowitcs R, Murphy W, Rothschild B, Segal M, Sokoloff L, Wolfe F. 1986. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 29: 1039-1049.
3. Banno N, Akihisa T, Ya sukawa K, Tokuda H, Tabata K, Nakamura Y, Nishimura R, Kimura Y, Suzuki T. 2006. Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J Ethnopharmacol 107(2): 249-253.
4. Brooks LO, Rolfe MI, Cheras PA, Myers SP. 2004. The comprehensive osteoarthritis test: a simple index for measurement of treatment effects in clinical trials. J Rheumatol 31(6): 1180-1186.
5. Bruyere O, Collette JH, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, Seidel L, Reginster JY. 2003. Biochemical markers of bone and cartilage remodeling in prediction of progression of knee osteoarthritis. J Rheumatol 30(5): 1043-1050. (Pubitemid 36529629)
6. Buckwalter JA, Saltzman C, Brown T. 2004. The impact of osteoarthritis: implications for research. Clin Orthop 427: 6-15.
7. Cheras PA. The role of thrombosis in ischaemic necrosis of bone (INB) and primary osteo-arthritis (OA). 1993. Doctoral thesis. The University of Queensland.
8. Cheras PA. 1997. Role of hyperlipidemia, hypercoagulability and hypofibrinolysis in osteonecrosis and osteoarthritis. In Osteonecrosis-Etiology, diagnosis and treatment, Urbaniak JR and Jones JP (eds). American Orthopaedic Association. Rosemont, Ill USA.
9. Cheras PA, Whitaker AN, Blackwell EA, Sinton TJ, Chapman MD, Peacock KA. 1997. Hypercoagulability and hypofibrinolysis in primary osteoarthritis. Clin Orthop 334: 57-67.
10. Christgau S, Henrotin Y, Tankó LB, Rovati LC, Collette J, Bruyere O, Deroisy R, Reginster JY. 2004. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 22(1): 36-42. (Pubitemid 38232807)
11. Conrozier T, Carlier MC, Mathieu P, Colson F, Debard AL, Richard S, Favret H, Bienvenu J, Vignon E. 2000. Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study. Ann Rheum Dis 59(10): 828-831.
12. Findlay DM. Vascular pathology and osteoarthritis. 2007. Rheumatology (Oxford) 46: 1763-1768.
13. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD. 2002. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46(10): 2613-2624. (Pubitemid 36118924)
14. Ghosh P, Cheras PA. 2001. Vascular mechanisms in osteoarthritis. Best Pract Res Clin Rheumatol 15(5): 693-709.
15. Goldstein H. 1999. Multilevel multilevel statistical models. In An introduction to basic and advanced multilevel modeling (2nd edn), Snijders TAB, Bosker RJ (eds). Edward Arnold: London.
16. Hall JB, Aebischer DP, Tomlinson HF, Osei-Amaning E, Hindle JR. 1996. Vitellaria paradoxa: A monograph. School of Agricultural and Forest Sciences: University of Wales, Bangor, UK; 105 pp.
17. Hulejová H, Baresová V, Klézl Z, Polanská M, Adam M, Senolt L. 2007. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 38(3): 151-156. (Pubitemid 47248299)
18. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. 2004. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364(9450): 2021-2029. (Pubitemid 39593078)
19. Lohmander LS, Ionescu M, Jugessur H, Poole AR. 1999. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 42(3): 534-544. (Pubitemid 29136102)
20. Murphy L, Schwartz TA, Helmick CG, Renner JB, Tudor G, Koch G, Dragomir A, Kalsbeek WD, Luta G, Jordan JM. 2008. Arthritis Rheum 59(9): 1207-1213.
21. Otterness IG, Swindell AC, Zimmerer RO, Poole AR, Ionescu M, Weiner E. 2000. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 8(3): 180-185. (Pubitemid 30304185)
22. Penninx BW, Abbas H, Ambrosius W, Nicklas BJ, Davis C, Messier SP, Pahor M. 2004. Inflammatory markers and physical function among older adults with knee osteoarthritis. J Rheumatol 31(10): 2027-2031. (Pubitemid 39336730)
23. Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C, Garnero P. 2007. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression. Rheumatology (Oxford) 46(6): 938-943. (Pubitemid 47062500)
24. Stürmer T, Brenner H, Koenig W, Günther KP. 2004. Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis 63(2): 200-205.
25. Takada Y, Aggarwal BB. 2003. Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol 171(6): 3278-3286. (Pubitemid 37093555)